UCB stock after-hours at EUR 207.50: minus 2.95 percent versus Lang & Schwarz prior close
Published on 09/29/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB stock was at EUR 207.50 after-hours at 8:50 p.m. CEST on September 29, 2026, according to Lang & Schwarz. The price was down 2.95 percent versus the Lang & Schwarz prior close of EUR 213.80.
Trading day in Brussels
The Lang & Schwarz quote represents an after-hours indication for investors in Germany following the Xetra session. The quote showed a bid of EUR 207.10 and an ask of EUR 207.90.
UCB highlights myasthenia gravis data
Separately, UCB said it will present data from its generalized myasthenia gravis portfolio at the American Association of Neuromuscular & Electrodiagnostic Medicine Congress annual meeting and the Myasthenia Gravis Foundation of America Scientific Session in Orlando from September 29 through October 2. The PR Newswire release said the presentations include post hoc analyses of minimal symptom expression in patients treated with zilucoplan or rozanolixizumab.
The company also said interim data from a Phase 1b study of cizutamig, an investigational BCMA×CD3 T-cell engager, will be presented. UCB stated that cizutamig’s safety and efficacy have not been established and that the candidate is not approved by the U.S. Food and Drug Administration or any other health authority. The same release said UCB acquired cizutamig through its acquisition of Candid Therapeutics.
Earlier U.S. agreement
In a separate August 31 announcement, UCB said it had reached an agreement with the U.S. government covering medicine access, future pricing practices and continued U.S. manufacturing investment. Specific terms remained confidential, according to the company’s official release.
